Phase 1 Clinical Study of TS-071 in Healthy Adult Male Subjects (Single-Dose Administration)

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222304

Enrollment

Registered

2013-11-21

Start date

2013-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese male subjects

Interventions

investigational material(s) Generic name etc : TS-071 INN of investigational material : luseogliflozin Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy Japanese male subjects etc.

Exclusion criteria

Exclusion criteria: Subjects with cardiovascular disorder, hepatic/biliary disorder, gastrointestinal disorder, urological disorder, renal disorder, endocrine disorder, immunological disorder, malignant tumor, diabetes mellitus, abnormal glucose tolerance, or respiratory disorder (such as pulmonary disease) etc.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameters, amounts of urinary glucose excretion, etc.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026